Piramed Limited, a biotech company, discovers and develops new medicines for the treatment of cancer and immune inflammatory disorders. The company focuses on the discovery and development of inhibitors to find clinical utility in various diseases, including cancer, immune inflammatory disorders, cardiovascular disease, and pain, as well as metabolic and infectious diseases. The company was incorporated in 2001 and is based in Slough, the United Kingdom. As of May 23, 2008, Piramed Limited operates as a subsidiary of Hoffmann-La Roche Inc.
Funding Rounds (1) - $13.2MUpdate
|Apr 15, 2008||firstwordpharma.com - Roche acquires Piramed for $160 million|
|Apr 15, 2008||in.reuters.com - Roche acquires UK biotech Piramed for $160 million|
|Jul 9, 2003||PRNewswire UK All - JPMorgan Partners and Merlin Biosciences Lead £8 ($13.2) Million Series A Investment... -- London, July 09 /PR Newswire UK/ --|
957 Buckingham Avenue
Slough, SL1 4NL